Dendreon Pharmaceuticals LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$16.3M
Doctors Paid
9,514
Transactions
61,024
2024 Total
$1.8M
Payment Breakdown by Category
Research$11.5M (70.7%)
Food & Beverage$1.6M (10.1%)
Consulting$959,142 (5.9%)
Travel$239,345 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.5M | 1,762 | 70.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 896 | 11.8% |
| Food and Beverage | $1.6M | 57,082 | 10.1% |
| Consulting Fee | $959,142 | 406 | 5.9% |
| Travel and Lodging | $239,345 | 742 | 1.5% |
| Education | $2,108 | 136 | 0.0% |
Payments by Type
Research
$11.5M
1,762 transactions
General
$4.8M
59,262 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT | $3.2M | 0 | 295 |
| A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER | $2.9M | 0 | 751 |
| OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER (PROVENT) | $2.4M | 0 | 392 |
| A RANDOMIZED PHASE 2 STUDY OF SIPULEUCEL-T WITH OR WITHOUT RADIUM-223 IN MEN WITH ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC BONE-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $695,523 | 0 | 14 |
| ProvONE Study | $684,938 | 0 | 88 |
| A RANDOMIZED PHASE 2 TRIAL OF IMMEDIATE VS. DELAYED ANTI-CTLA4 BLOCKADE FOLLOWING SIPULEUCEL-T TREATMENT FOR PROSTATE CANCER IMMUNOTHERAPY | $213,299 | 0 | 5 |
| A STUDY TO EVALUATE CHARACTERISTICS PREDICTIVE OF A POSITIVE IMAGING STUDY FOR DISTANT METASTASES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREDICT | $177,661 | 1 | 72 |
| BIOLOGIC TISSUE EFFECT OF SIPULEUCEL-T ON METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | $147,752 | 0 | 9 |
| Biologic Tissue Effect OF Sipuleucel-T on Metastatic Castration-resistant Prostate Cancer | $147,686 | 0 | 2 |
| EVALUATION OF LYMPH NODE METASTAASES IN MEN UNDERGOING TREATMENT WITH SIPULEUCEL-T FOR METASTATIC CASTRATED-RESISTANT PROSTATE CANCER | $138,222 | 0 | 1 |
| IMMUNE EVALUATION STUDY OF SIPULEUCEL-T IN AFRICAN AMERICAN MEN WITH CASTRATE RESISTANT PROSTATE CANCER | $127,500 | 0 | 1 |
| CLINICAL STUDY OF ATEZOLIZUMAB ANTI-PD-L1 AND SIPULEUCEL-T IN PATIENTS WHO HAVE ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $120,135 | 0 | 9 |
| A Phase II CTLA4 Blockade Combined with Sipuleucel-T (Provenge) for Prostate Cancer Immunotherapy | $91,720 | 0 | 2 |
| RETROSPECTIVE REVIEW EVALUATING THE PSA CHANGES IN PATIENT WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER AFTER SIPULEUCEL-T TREATMENT | $79,514 | 0 | 1 |
| CYT107 AFTER VACCINE TREATMENT PROVENGE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | $66,796 | 0 | 1 |
| ROSSER-2015-4CLINICAL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1) AND SIPULEUCEL-T IN PATIENTS WHO HAVE ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $58,159 | 0 | 2 |
| IMPACT OF HIGH-DOSE, SINGLE FRACTION RADIATION ON IMMUNOGENICITY OF SIPULEUCEL-T IN METASTATIC CASTRATION RECURRENT PROSTATE CANCER PATIENTS | $42,609 | 0 | 1 |
| A PHASE II CTLA4 BLOCKADE COMBINED WITH SIPULEUCEL-T PROVENGE FOR PROSTATE CANCER IMMUNOTHERAPY | $41,477 | 0 | 1 |
| A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF SIPULEUCEL-T WITH CONCURRENT VERSUS SEQUENTIAL ADMINISTRATION OF ABIRATERONE ACETATE PLUS PREDNISONE IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $31,613 | 0 | 49 |
| A PHASE II RANDOMIZED STUDY OF SIPULEUCEL-T WITH OR WITHOUT CONTINUING NEW HORMONAL AGENTS (NHA) IN METASTATIC PROSTATE CANCER WITH PSA PROGRESSION WHILE ON NHA AND LHRH ANALOG | $31,245 | 0 | 1 |
| A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER | $28,120 | 0 | 21 |
| PILOT TRIAL OF SIPULEUCEL-T, WITH OR WITHOUT PTVG-HP DNA BOOSTER VACCINE, IN PATIENTS WITH CASTRATE-RESISTANT, METASTATIC PROSTATE CANCER | $26,266 | 0 | 1 |
| CLINICAL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1) AND SIPULEUCEL-T IN PATIENTS WHO HAVE ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $19,645 | 0 | 4 |
| A STUDY OF SIPULEUCEL-T WITH ADMINISTRATION OF ENZALUTAMIDE IN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $14,454 | 0 | 4 |
| A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF SIPULEUCEL-T WITH CONCURRENT VERSUS SEQUENTIAL ADMINISTRATION OF ENZALUTAMIDE IN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $11,680 | 0 | 25 |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2 Urothelial Carcinoma | $6,845 | 0 | 1 |
| IMMUNE MONITORING PROTOCOL IN MEN WITH PROSTATE CANCER ENROLLED IN A CLINICAL TRIAL OF SIPULEUCEL-T | $1,539 | 0 | 8 |
| A SYSTEMS BIOLOGY APPROACH TO IMMUNE MONITORING IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER RECEIVING SIPULEUCEL-T | $1,200 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Mark Scholz, M.d, M.D | Specialist | Marina Del Rey, CA | $10,113 | $0 |
| Sukumar Ethirajan, M.d, M.D | Hematology & Oncology | Overland Park, KS | $8,750 | $0 |
| Mr. Glenn Cline, Aprn, Fnp-Bc, APRN, FNP-BC | Family | Gahanna, OH | $8,516 | $0 |
| David Penson, M.d, M.D | Urology | Nashville, TN | $8,490 | $0 |
| Ralph Henderson, M.d, M.D | Urology | Shreveport, LA | $8,407 | $0 |
| Zachary Reardon, Md, MD | Urology | Mobile, AL | $8,237 | $0 |
| Dr. Jose De La Cerda, M.d, M.D | Urology | San Antonio, TX | $8,232 | $0 |
| Dr. Joshua Perkel, M.d, M.D | Urology | Macon, GA | $8,211 | $0 |
| Gordon Brown, Do, DO | Urology | Cherry Hill, NJ | $8,184 | $0 |
| Lawrence Newman, Md, MD | Urology | Las Vegas, NV | $8,067 | $0 |
| Jacob Ark, M.d, M.D | Urology | Saint Louis, MO | $7,876 | $0 |
| Eric Mitchnick, Md, MD | Urology | Port Jefferson Station, NY | $7,702 | $0 |
| Dr. David Taylor, M.d, M.D | Urology | Morristown, NJ | $7,572 | $0 |
| Kishore Dass, M.d, M.D | Radiation Oncology | Wellington, FL | $7,471 | $0 |
| Michael Sherman, M.d., Phd, M.D., PHD | Hematology & Oncology | Walnut Creek, CA | $7,120 | $0 |
| Dr. Roscoe Nelson, Md, MD | Urology | American Fork, UT | $6,976 | $0 |
| Dr. Steve Freedland, M.d, M.D | Urology | West Hollywood, CA | $6,724 | $0 |
| Frank Tortora, M.d, M.D | Urology | Cary, NC | $6,607 | $0 |
| Dr. Michael Johnson, Md, MD | Urology | Saint Louis, MO | $6,580 | $0 |
| Sanford Siegel, M.d, M.D | Urology | Owings Mills, MD | $6,530 | $0 |
| Mrs. Pamela Jones, R.n., N.p, R.N., N.P | Family | Troy, MI | $6,432 | $0 |
| Dr. James Russo, M.d, M.D | Diagnostic Radiology | Lafayette, LA | $6,423 | $0 |
| Dr. Walter Rayford, M.d., Phd., Facs, M.D., PHD., FACS | Urology | Memphis, TN | $6,319 | $0 |
| Robert Hoy, Pa-C, Mpas, PA-C, MPAS | Physician Assistant | Tucson, AZ | $6,312 | $0 |
| Dr. Aihua Yen, M.d, M.D | Medical Oncology | Houston, TX | $6,107 | $0 |
About Dendreon Pharmaceuticals LLC
Dendreon Pharmaceuticals LLC has made $16.3M in payments to 9,514 healthcare providers, recorded across 61,024 transactions in the CMS Open Payments database. In 2024, the company paid $1.8M. The top product by payment volume is PROVENGE ($16.1M).
Payments were distributed across 144 medical specialties. The top specialty by payment amount is Urology ($3.3M to 3,858 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($959,142), Research ($11.5M), Travel & Lodging ($239,345).
Dendreon Pharmaceuticals LLC is associated with 1 products in the CMS Open Payments database.